Welcome to OncoStemCell.com
OncoStemCell™ Technology is a revolutionary 3D cell culture system that selects and enriches the cancer stem cell (CSC) subpopulation in tumors at a high stem cell fraction, exceeding 80%. Unlike cancer cells cultured on 2D plates or spheroids grown in suspension or naturally-based 3D matrices, which have low fraction of CSC’s (less than 10%), cancer cells cultured in our system can more efficiently identify new biomarkers for the development of specific therapies and advanced treatment regimens, and above all, can dramatically reduce the time needed for drug discovery. Our system allows for a more reliable and accurate model for in vitro screening of CSC targeting drugs compared with competing products in the market. A more reliable in vitro model with patient-derived CSC’s has the potential to significantly decrease pre-clinical screening cost and reduce the chance of late-stage failure of the drug candidate in clinical trials. The target market for OncoStemCell technology is pharmaceutical companies developing therapies targeting CSCs of the tumor tissue.
Cancer Stem Cells (CSC) have the ability to resist therapy and initiate a recurrence which make them an important therapeutic target. Future research is essential to elucidate how CSC's dictate metastasis, therapy-resistance or immune-scape signature. However, without having reliable markers it will be a challenging pursuit. An exact molecular characterization of this small sub-population in the tumor tissue requires the development of specific CSC markers and suitable enrichment methods. By utilizing our innovative, high-throughput screening technologies, pharmaceutical companies can expect valuable insights regarding suitable CSC-associated biomarkers. This will lead to new therapeutic approaches targeting CSC's and individualized cancer therapy.
